Compare Amgen, Inc. (AMGN) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Amgen, Inc. trades at $415.69 (market cap $224.14B), while iShares 10 20 Year Treasury Bond ETF trades at $96.73. The key difference: Amgen, Inc. pays a 2.43% dividend while iShares 10 20 Year Treasury Bond ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | TLH | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Fixed Income |
52-Week High | $417.20 | $105.36 |
52-Week Low | $271.18 | $96.39 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
TLH trades at $96.86, up 0.49% today, but technical indicators signal a bearish trend with moving averages and ADX pointing downward. The stock lacks disclosed financial ratios, limiting fundamental clarity. Recent corporate actions include consistent dividend payments, with the latest being $0.38 per share scheduled for August 2026. Market sentiment is influenced by broader economic factors like rising Treasury yields and oil price volatility, as highlighted in recent financial news.
The outlook for TLH is cautious due to weak technical momentum and absent key financial metrics, though dividend stability offers some support. Risks include macroeconomic pressures from potential Fed rate hikes and inflation. Investors should seek updated earnings reports for fundamental reassessment, as current data gaps hinder a full evaluation of growth prospects or valuation attractiveness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
